SATELLITE SYMPOSIA

GENZYME SATELLITE SYMPOSIUM
Saturday 11 September 2010 - 2:00 pm - 6:00 pm

Practical Management of Thyroid Cancer:
State of the Art & perspectives

1.15 pm | Welcome Reception

2.00 pm | Welcome & opening remarks
M. Schlumberger (France)

Session 1: Use of Radioiodine in the Management of Thyroid Cancer
Chair: M.Tuttle (USA)

2.10 pm | Radioiodine: An historical vignette
E. Mazzaferri (USA)

2.20 pm | High-risk patient: Interactive case study 1 & panel discussion/Q & A
M. Tuttle (USA)

2.45 pm | Low-risk patient: Interactive case study 2 & panel discussion/Q & A
M.Tuttle (USA)

3.00 pm | Low-risk patients: To ablate or not to ablate - an interactive debate
G. Doherty, R. Kloos (USA)

3.30 pm | Session 1 panel discussion/Q & A
Expert Panel 1

3.50 - 4.15 pm | Coffee break

Session 2: Diagnostic Follow Up and Monitoring of the Thyroid Cancer Patient
Chair: D. Cooper (USA)

4.15 pm | Diagnostic follow up: An historial vignette
E.Mazzaferri (USA)

4.25 pm | Diagnostic follow up: best practice
F. Pacini (Italy)

4.40 pm | Low-risk patient: Interactive case study
D. Cooper (USA)

4.55 pm | PSession 2 panel discussion/Q & A
Expert Panel 2

Breaking News - Results of the 1st International Patients' Survey of Thyroid Cancer Care
Chair: M. Luster (Germany)

5.15 pm | Results - the patient journey - diagnosis, treatment, impact
M. Luster (Germany), K. Farnell (UK)

5.30 pm | Q & A
M. Luster (Germany)

5.50 pm | Closing remarks
M. Schlumberger (France)

6.00 pm | Close

Expert Panels
Panel 1: M. Tuttle (USA) – Chair, W.Y. Chung (Korea), G. Doherty (USA), R. Elisei (Italy), R. Kloos (USA), M. Luster (Germany), F. Pitoia (Argentina)
Panel 2: D. Cooper (USA) – Chair, G. Doherty (USA), M. Hoffmann (Austria), F. Pacini (Italy), F. Pitoia (Arg.), J.W.A. Smit (Netherlands), M. Tuttle (USA)

ASTRA ZENECA SATELLITE SYMPOSIUM
Sunday 12 September 2010 6:30 pm - 7:30 pm

Improving outcomes in thyroid cancer: has targeted therapy delivered?
Chairs: Martin Schlumberger (Paris, France), Samuel Wells (Bethesda, USA)

Welcome and introduction
Martin Schlumberger (Paris, France)

Defining the unmet needs in advanced medullary thyroid cancer
Richard Kloos (Columbus, USA)

Medullary thyroid cancer - has targeted therapy delivered?
Samuel Wells (Bethesda, USA)

Beyond medullary thyroid cancer – overview and introduction
Martin Schlumberger (Paris, France)

Beyond medullary thyroid cancer – targeted therapy for other thyroid cancers
Lars Bastholt (Odense, Denmark)

Concluding remarks
Samuel Wells (Bethesda, USA)

MERCK SERONO SATELLITE SYMPOSIUM
Sunday 12 September 2010 6:30 pm - 7:30 pm

The Thyroid and Diabetes
Chair: Jacques Orgiazzi (Lyon, France)

Welcome and introduction
Jacques Orgiazzi (Lyon, France)

Thyroid and carbohydrate metabolism
Georg Brabant (Manchester, UK)

Managing patients with thyroid disorders and diabetes type I and II
Leonidas Duntas (Athens, Greece)

Thyroid hormones and analogues on metabolism regulation
Antonio Bianco (Miami, USA)

BAYER SATELLITE SYMPOSIUM
Monday 13 September 2010 7:30 am - 8:30 am

Treatment of Differentiated Thyroid Cancer (DTC)
in the Era of Targeted Therapy

7.30 pm | Welcome and Introduction
Martin Schlumberger (Villejuif, France)

7.35 pm | Epidemiology, Diagnosis, and Unmet Need of DTC
Yasuhiro Ito (Kobe, Japan)

7.50 pm | Inherent Biology and Signaling Pathways in DTC
Johannes Smit (Leiden, Netherlands)

8.05 pm | Clinical Development of Targeted Therapies in DTC
Marcia Brose (Philadelphia, USA)

8.20 pm | Panel Discussion

8.30 pm | Concluding Remarks
Martin Schlumberger (Villejuif, France)

DIAGNOSTIC HYBRIDS Inc. SATELLITE SYMPOSIUM
Monday 13 September 2010 6:30 pm - 7:30 pm

“Novel diagnostic tool for Graves’ disease”
Chairs: George J. Kahaly (Mainz, Germany), Len D. Kohn (Ohio, USA)

Role and structure of the TSH receptor in Graves’ disease
Rebecca Bahn (Rochester, USA)

Development and FDA clearance of a novel bioassay for stimulating TSH receptor
autoantibodies (Thyretain®)
Paul D. Olivo (Athens, USA)

Thyretain® in pediatric Graves’ disease
Rosaline Brown (Boston, USA)

Thyretain® is a functional indicator of Graves’ thyroidal and orbital disease
Katharina A. Ponto (Mainz, Germany)

Round-table discussion

IBSA INSTITUT BIOCHIMIQUE SATELLITE SYMPOSIUM
Monday 13 September 2010 6:30 pm - 7:30 pm

Levothyroxine softgel capsules: an innovative formulation targeting
thyroxine absorption and malabsorption
Chairs: Aldo Pinchera (Pisa, Italy), Kenneth D. Burman (Washington, USA)

6.30 pm | Welcome and introduction
Aldo Pinchera (Pisa, Italy)

6.35 pm | The new FDA quality requirements and the bioavailability of levothyroxine softgel capsules
Murray P. Ducharme (Montreal, Canada)

6.45 pm | Nutritional interferences on levothyroxine absorption
Salvatore Benvenga (Messina, Italy)

7.00 pm | Gastrointestinal malabsorption of levothyroxine
Marco Centanni (Latina, Italy)

7.15 pm | Conclusions
Kenneth D. Burman (Washington, USA)

7.25 pm | Discussion

7.30 pm | End of session